Combination Drugs: Adding Up the Opportunities - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Combination Drugs: Adding Up the Opportunities
Fixed-dose combination drug therapies give rise to innovation in solid-dosage formulations and manufacturing.


Pharmaceutical Technology
Volume 36, Issue 10, pp. 40-47, 127

References

1. Code of Federal Regulations, Title 21, Food and Drugs (Government Printing Office, Washington, DC), Chapter I, Part 3, Subchapter A, Sec. 3.2 (e).

2. FDA, FY 2011 Performance Report to Congress for the Office of Combination Products (Rockville, MD).

3. FDA, "Frequently Asked Questions About Combination Products" (Rockville, MD), http://www.fda.gov/CombinationProducts/AboutCombinationProducts/ucm101496.htm, accessed Sept. 15, 2012.

4. Code of Federal Regulations, Title 21, Food and Drugs (Government Printing Office, Washington, DC) Chapter 1, Part 300, Subpart B, Sec. 300.50.

5. FDA, FDA Approved Drugs, Drugs@FDA, accessed Sept. 15, 2012.

6. A. Kane, D. Monterroza, and C. Salazar, "Unlocking the Power of New Softgel Technology for Multiple Formulations" Webcast, Pharm. Technol., http://www.PharmTech.com/apiformulations/, accessed Sept. 15, 2012.

7. FDA, Label for Janumet XR (Rockville, MD, 2012).

8. FDA, Label for Juvisync (Rockville, MD, 2011).

9. FDA, Label for Qsymia (Rockville, MD, 2012).

10. FDA, Label for Jalyn (Rockville, MD, 2010).

11. FDA,Label for Suboxone Sublingual Film (Rockville, MD, 2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here